VEEVA-SYSTEMS
12.10.2020 13:05:13 CEST | Business Wire | Press release
Veeva Systems (NYSE: VEEV) today announced that Roche (SWX: ROG) has selected Veeva Development Cloud applications globally to streamline clinical, regulatory, and quality processes. The company is switching to unified applications in Vault Clinical , Vault RIM , and Vault Quality suites to increase efficiency, enhance data quality, and drive compliance throughout the product lifecycle.
“Speeding drug development and product supply are strategic priorities for innovative life sciences companies like Roche,” said Rik Van Mol, vice president of Veeva Development Cloud. “Veeva Development Cloud breaks down system and process silos so life sciences companies can more quickly bring innovative treatments to patients.”
Roche is standardizing on clinical applications Vault eTMF and Vault CTMS , regulatory applications Vault Submissions , Vault Registrations , and Vault Submissions Archive , and quality applications Vault QMS and Vault QualityDocs .
Learn more about Veeva Vault Development Cloud at the upcoming Veeva R&D and Quality Summit , October 13-14, 2020. The virtual event is open to life sciences industry professionals. Register and stay up to date on program details at veeva.com/Summit .
Additional Information
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is a leader in cloud solutions—including data, software, and services—for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 900 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. The company is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu .
Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended July 31, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov . Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
® 2020 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo are trademarks of Veeva Systems Inc.
Veeva Systems Inc. owns other registered and unregistered trademarks.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201012005167/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The 2026 NAB Show Wraps with Proof the Future of Media and Entertainment is Expanding Beyond Broadcasting23.4.2026 01:52:00 CEST | Press release
The Show’s growing community of creators, enterprise media teams and leaders in sports media is driving the next era of storytelling The 2026 NAB Showwrapped today, welcoming more than 58,000 registered attendees and reaffirming its place at the center of the global media and entertainment evolution. Driven by an expanding community of creators, enterprise media teams and leaders in sports media, the Show has brought in new audiences and sparked new collaborations. The 2026 NAB Show didn’t just reflect where the industry is; it pushed it forward, strengthening its status as the must-attend marketplace for the future of storytelling and content innovation. “The 2026 NAB Show captured the energy and transformation driving today’s media and entertainment landscape, unveiling powerful new tools and technologies that put storytelling in everyone’s hands,” said Karen Chupka, executive vice president of NAB Show. “This year, we brought together a truly global community to spark innovation, el
ASP Announces Strategic Partnership With ChemDAQ to Advance Safety, Confidence, and Compliance in Sterile Processing23.4.2026 01:42:00 CEST | Press release
Advanced Sterilization Products (ASP), a global leader in infection prevention and low‑temperature sterilization, today announced a strategic partnership with ChemDAQ, a leading provider of hazardous gas detection and monitoring solutions. Together, ASP and ChemDAQ will support healthcare organizations by strengthening safety practices, reinforcing regulatory confidence, and advancing best‑in‑class sterile processing environments. As part of this partnership, ASP and ChemDAQ collaborated on evidence rooted in industry engagement and thought leadership to help sterile processing professionals stay ahead of evolving standards and guidance, including AAMI ST58 and other recommendations related to sterilant exposure and workplace safety. These efforts underscore ASP’s commitment to continuous improvement and practical innovation that meets real‑world needs. This collaboration reflects ASP’s role as a trusted advisor to sterile processing professionals, bringing together proven low‑temperat
TSMC Debuts A13 Technology at 2026 North America Technology Symposium22.4.2026 21:00:00 CEST | Press release
Newest Node Pushes Density Scaling and Energy Efficiency to New Heights to Address Industry’s Most Demanding Applications TSMC (TWSE: 2330, NYSE: TSM) today debuted its latest innovation in its most advanced process technology at the Company’s 2026 North America Technology Symposium. TSMC’s new A13 process is a direct shrink of its industry-leading A14 node announced in 2025, enabling even more compact and efficient designs to address insatiable customer demand in computational requirements for next-generation artificial intelligence, high-performance computing (HPC), and mobile applications. Representing TSMC’s commitment to continuous improvement, A13 provides 6% area savings from A14. Design rules are fully backward compatible with A14, enabling customers to quickly migrate their designs to TSMC’s latest nanosheet transistor technology. In addition, A13 delivers increased power efficiency and performance gains through design-technology co-optimization, and is scheduled to enter prod
Galderma Shareholders Approve All Annual General Meeting Proposals22.4.2026 17:45:00 CEST | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, announced that shareholders approved all proposals put forward by the Board of Directors at its Annual General Meeting (AGM), held earlier today via live webcast. This includes the payment of a gross dividend of 0.35 CHF per dividend-bearing share1, to be distributed out of reserves from capital contributions. Shareholders approved the election of Harry Kirsch as independent member of the Board of Directors, as well as the election of Samuel du Retail and Delphine Viguier-Hovasse, representatives of L’Oréal, as non-independent members of the Board. In addition, Thomas Ebeling (Chair), Daniel Browne, Maria Teresa Hilado, Karen Lee Ling, Roberto Marques, Sherilyn McCoy and Dr. Flemming Ørnskov were re-elected to the Board. The AGM also approved the company’s 2025 Annual Financial Statements, Non-Financial Report and Compensation Report. Detailed voting results and the official minutes will be published on Galderma's
Altrove and Bloomineral Named Winners of the 2026 Grand Prix ACF AutoTech22.4.2026 15:21:00 CEST | Press release
IoT.Bzh receives the inaugural Industrialization Prize at the 9th edition of the international automotive startup competition Altrove and Bloomineral have been crowned winners of the 2026 Grand Prix ACF AutoTech, the international startup competition recognizing the best of automotive innovation. The ninth edition was held on Wednesday, April 15 at the Automobile Club de France in Paris, where IoT.Bzh also received the first-ever Industrialization Prize. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422236542/en/ Picture of the end of the event with the winners : Bloomineral, Altrove and Iot.Bzh + all the Jury Members from French Automotive OEM and Tier1 Hosted by competition founder Richard de Cabrol and Simon Degiovanni, the evening gathered more than 250 leaders from the automotive, technology, digital, business and media sectors, with attendees joining both on-site and online. Six finalist startups, selected from mor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom